id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-274331-0i2opmcn	Wang, Catherine J.	COVID‐19 infection on IL‐23 inhibition	2020-07-14		.txt	text/plain	388	32	53	Given mild symptoms, the patient was discharged. The patient was discharged 1 week later on home quarantine. The patient in this manuscript has given informed consent to publication of his case details. In our case, the patient recovered from COVID-19 before his next scheduled risankizumab dose. However, more data needs to be obtained about biologics in COVID-19 patients, in particular whether or not biologic dosage timeline should be adjusted based on resolution of infection. A database to collect information on COVID-19 patients on biologic therapy and their outcomes would be instrumental to guide clinicians on best practices for now and in future pandemics. In conclusion, this case illustrates that IL-23 inhibition via biologic therapy in COVID-19 may not correlate with severe respiratory disease. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor	./cache/cord-274331-0i2opmcn.txt	./txt/cord-274331-0i2opmcn.txt